Major pharmaceutical and diagnostic equipment company Roche recently integrated a suite of AI algorithms into its enterprise digital pathology software.
The company is partnering with a Korean company Deep Bio DeepDx Prostate, a prostate cancer analytics AI solution, is being integrated into the navify digital pathology platform, enabling pathologists with AI technology to perform gland-level Gleason grading, tissue and tumor measurements, and diagnostic support.
DeepDx Prostate has been extensively tested in the United States, analyzing over 700,000 core needle biopsies, and has received regulatory approval in Europe.
Singapore based Critiv The company also announced that it will integrate its digital pathology AI solutions into Roche’s navify.
It includes AI modules for detecting colon, prostate, breast and gastric cancer from whole slide images.These solutions also provide tumor grading.
Meanwhile, mental health startups Wonder Site The Indian company has raised $400,000 in seed funding in a round led by Inflection Point Ventures.
Founded in 2022, the company currently offers six virtual reality-based digital therapeutic products to treat mental, behavioral and neurocognitive health conditions, including substance use disorders, OCD, anxiety, phobias and autism.
The startup plans to use the new funding to secure more partnerships across India and further develop its VR-based mental health solutions, according to a press release. Currently operating in three major cities, Wundrsight said its VR solutions are being used in more than five hospitals and have already been used to treat around 1,000 patients.
